statins are the most effective drugs available for lowering ldl and have revolutionized cardiovascular medicine. However, despite the widespread use of statins, many patients do not attain ldl goals and this is especially true in high and very high-risk patients in whom the ldl goals are even lower. Therefore, there is a demand for more potent statins.

rosuvastatin is the most potent statin for reducing ldl and was approved by us fda in august 2003. Rosuvastatin monotherapy may allow patients to attain ldl goals earlier and may help avoid combination therapy or potential adverse effects of high-dose statin therapy. Further, rosuvastatin has several advantages over all other statins- highest affinity for hmg-coa reductase, greater increase in hdl and fewer clinically significant drug interactions. In addition, rosuvastatin is the only statin to be approved by the us fda for slowing the progression of atherosclerosis. The safety profile of rosuvastatin is similar to other statins.

recently, the jupiter trial which showed significant reduction in cardiovascular events with rosuvastatin in healthy people with normal ldl and high c-reactive protein has added a new perspective in primary prevention therapy for statins. These results have the potential to revise guidelines and can have a huge impact on clinical practice.

rosulip is currently available in two strengths: rosulip 5 (5 mg rosuvastatin) and rosulip 10 (10 mg rosuvastatin). The dosage range of rosulip is 5-40 mg once daily at any time of the day and independent of food.